Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23646279 | 1.00 | ITGB3 (0.48) | ITGB3ITGA2BPRMT1ADRA1AKMT2A | |
| SCHEMBL23646286 | 1.00 | ITGB3 (0.48) | ITGB3ITGA2BPRMT1ADRA1AKMT2A | |
| SCHEMBL23646277 | 1.00 | ITGB3 (0.48) | ITGB3ITGA2BPRMT1ADRA1AKMT2A | |
| SCHEMBL23646283 | 0.83 | ITGB3 (0.52) | ITGB3ITGA2BPRMT1ADRA1AKMT2A | |
| SCHEMBL23646273 | 0.83 | ITGB3 (0.52) | ITGB3ITGA2BPRMT1ADRA1AKMT2A | |
| SCHEMBL23646232 | 0.83 | ITGB3 (0.52) | ITGB3ITGA2BPRMT1ADRA1AKMT2A | |
| SCHEMBL23646203 | 0.83 | ITGB3 (0.52) | ITGB3ITGA2BPRMT1ADRA1AKMT2A | |
| SCHEMBL23646249 | 0.82 | PRMT1 (0.41) | PRMT1ADRA1AEPHX2ALOX5MAPK1 | |
| SCHEMBL7362939 | 0.76 | ITGB3 (0.54) | ITGB3ITGA2BPRMT1ADRA1AEPHX2 | |
| SCHEMBL23646233 | 0.74 | HTT (0.62) | ITGB3ITGA2BPRMT1ADRA1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258324-B2 | Fatty acid analogues and methods of use | LIN BIOSCIENCE INC. (TW) | 2025-03-25 | — | — | US | disclosed |
| US-20210221781-A1 | FATTY ACID ANALOGUES AND METHODS OF USE | LIN BIOSCIENCE INC. (TW) | 2021-07-22 | — | — | US | disclosed |
| US-20210221781-A1 | FATTY ACID ANALOGUES AND METHODS OF USE | LIN BIOSCIENCE INC. (TW) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221781-A1 | FATTY ACID ANALOGUES AND METHODS OF USE | ELOVL1, FADS1, ALOX5 | ITGB3 2789/4885ITGA2B 2403/4885PRMT1 4275/4885 |
| US-12258324-B2 | Fatty acid analogues and methods of use | ELOVL1, FADS1, ALOX5 | ITGB3 2789/4885ITGA2B 2403/4885PRMT1 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.